References for: SENTENCE

Full identifier: http://www.w3.org/2000/01/rdf-schema#SENTENCE

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50).
Eva Zegelaar
2021-12-16T20:16:59.753Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50).
Eva Zegelaar
2021-12-16T20:16:57.456Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies.
Eva Zegelaar
2021-12-16T20:12:31.441Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with dexamethasone significantly reduced the number of cells expressing iNOS, but did not prevent primary demyelination.
Eva Zegelaar
2021-12-16T20:12:30.122Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:36.592Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:34.931Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:33.416Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:31.755Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:29.864Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:28.373Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:26.559Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:24.844Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:23.282Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:21.645Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:20.116Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:18.502Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:16.757Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:14.989Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:13.416Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:11.912Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:10.223Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:08.568Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:06.899Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:05.293Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:03.614Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:10:02.132Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:59.849Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:58.228Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:56.345Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:54.615Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:52.966Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:51.440Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:49.794Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:48.065Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:46.292Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:44.248Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-12-16T20:09:42.633Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-12-16T20:09:41.075Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-12-16T20:09:39.303Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-12-16T20:09:37.590Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-12-16T20:09:35.847Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-12-16T20:09:34.030Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-12-16T20:09:32.383Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns.
Eva Zegelaar
2021-12-16T20:09:16.820Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns.
Eva Zegelaar
2021-12-16T20:09:14.970Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:13.172Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:11.375Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:09.587Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:07.687Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:05.954Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:04.115Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:02.366Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:09:00.733Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:59.042Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:57.364Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-12-16T20:08:55.863Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-12-16T20:08:54.102Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-12-16T20:08:52.563Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-12-16T20:08:50.799Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-12-16T20:08:49.021Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-12-16T20:08:47.405Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:45.340Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:43.586Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:41.769Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:39.995Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:38.412Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:36.652Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:34.845Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:33.085Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:30.066Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-12-16T20:08:28.461Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:26.602Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:24.843Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:23.069Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:21.309Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:19.602Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:17.759Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:16.099Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:14.290Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:11.057Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:09.279Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:07.463Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:05.960Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:04.261Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:02.675Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:08:00.913Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:07:59.207Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:07:57.444Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:07:55.668Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:07:53.958Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:07:51.775Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-12-16T20:07:50.076Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:54.070Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:52.388Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:50.611Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:48.822Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:47.283Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:45.668Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:44.371Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-12-16T20:06:43.005Z
Showing 1 to 100 of 1000
<< 1 2 3 4 5 6 7 8 9 10 >>